LIVE POLIO IRUS VACCINES

626 Index
Poliomyelitis virus-continued
Type 3, Leon 12 a 1 b
in neutralization tests, 229
Type 3, Saukett
MS marker, 36
Poliomyelitis Research Foundation, USA, 86, 475
Polystyrene panels
pH tests in, 229
Population
immunological structure, 489
seroimmunity of, 510, 518
statistics, 147, 342, 437, 466-467, 522, 559, 581
theoretical graph of expected paralysis, 460
"Portals of entry"
immunologic resistance of tissues, 414
Potash, Louis, paper 144-155
Pox viruses
extensive variation, 110
Precentral gyrus
inflammatory lesions, 70, 73
Precipitation tests
in agar gel on slides, 243
Pregnancy
abortions among vaccinees, 372
effects in mothers and fetus, 601
masked response during, 214
significant antibody titer rise during, 211
trivalent vaccine during, 207-215
vaccine given during all trimesters, 437
Prem, Konald A., paper 207-227; 206, 269, 317, 372
Prenzie, Dr. - (of Belgium), 532
Preventive medicine
live vaccine and, 352
Propiolactone inactivated vaccine
conversion rate in France, 532
Protection
estimated in African children, 472
with Swedish inactivated vaccine, 593
Provoking effect
DPT vaccine, 597
no evidence, Philadelphia, 598
Przesmycki, Feliks, paper 522-531; 55, 506, 532
Publicity
communications media, 436, 569, 584
education programs, procedures of Sabin, 591
health education, 486, 584
in Dade County, Florida, 436, 454
in Minnesota, 462
information through medical societies, 569
volunteer basis, 420
Puebla, Mexico
vaccination program, 1958, 386
Pundit, Dr. - (of India), 598
Puntarenas province, Costa Rica
vaccination program, 1960, 563
Querétaro, Mexico, 381
Quirce, José Manuel, paper 561-573; 118, 174, 184
532, 574-575
Rabbits
vaccine test, 505
Rabies
tolerance induction in mice, 328
Radioactive phosphoriis
and polivirus, 41
distribution of radioactivity plotted, 266-267
Ralph, N. M., paper 413-428
Ramírez Vargas, María José, 118, 184
Ramos Alvarez, Manuel, paper 377-385, 386-409; 376-
377, 410-411
Rayon Sanitational and Epidemiological Centers, 487
rct, see Reproductive capacity temperature, T marker
Reactions, see also Vaccine associated cases
by clinical type and experimental group, 344
compared in vaccinees and placebo group, 343
evaluation, 345-346
fever, 430, 483
frequency in highly infected population, 394
in children after vaccine, 279
in spread study, 169
in vaccinated, listed, 279, 570
incidence, low in Soviet Union, 584
no significant illnesses, 146, 310, 314, 316, 386, 454,
497, 542, 547, 576, 580, 601
unrelated to vaccination, 6, 420, 566
urticaria, 448, 464
Recombination
and genetic instability between types, 574
evidence with polio, 110
Record system
described, 437
Reed and Muench, 68, 138, 208, 351
Refeeding
immunologic tolerance induced, 287
Registration
of vaccinated children, 487
Reinfection
of attenutiated virus, 537
of infant from family contact, 303
prevention in mass vaccinated communities, 410
rates after trivalent vaccine, 123
rates in chimpanzees, 158
resistance in gut and antibody response, 321
Replacement
of wild polio by Cox vaccine, 198
Reporting
completeness, 559
Reproductive capacity temperature
compared T marker, 101
Residual virus activity
estimation and plaque technique, 268
technique, 235-237
Respiratory spread diseases
intrafamily spread in same age groups, 202
Respiratory syncitial agent
vacuolating virus recovered from seed stocks, 80
Respiratory tract
parasitic population, 578
Resistance
measure, excretion with antibody rise, 602
Reticulo-endothelial system
damage and polio risk, 461
Reutovo, USSR, 242
Revaccination
in infants if poor first response, 220
trivalent vaccine, 123